首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1899964

治疗性疫苗市场规模、份额和成长分析（按产品、技术和地区划分）－2026-2033年产业预测

Therapeutic Vaccines Market Size, Share, and Growth Analysis, By Products (Addiction Vaccines, Autoimmune Disease Vaccines), By Technology (Autologous vaccines, Allogeneic vaccines), By Region - Industry Forecast 2026-2033

出版日期: 2025年12月26日 | 出版商:

SkyQuest | 英文 215 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球治疗性疫苗市场规模预计在 2024 年达到 593.5 亿美元，从 2025 年的 655.8 亿美元成长到 2033 年的 1,457.7 亿美元，在预测期（2026-2033 年）内复合年增长率为 10.5%。

随着疫苗被接种到接受慢性病治疗的患者体内以增强其免疫反应并提高康復几率，治疗性疫苗市场正经历显着增长。慢性病盛行率的不断上升，以及对创新疫苗研发投入的持续成长，预计将推动市场扩张。此外，全球范围内预防保健意识的提高和对个人化医疗日益增长的需求，也进一步推动了对治疗性疫苗的需求。然而，复杂的研发流程和有限的疗效等挑战可能会阻碍市场的长期发展。为了抓住新的机会，治疗性疫苗公司可以考虑在不断变化的医疗保健环境中，将疫苗与各种免疫疗法和精准医疗策略相结合。

全球治疗性疫苗市场驱动因素

全球感染疾病和慢性病盛行率的不断上升，引发了公众对医疗保健的日益关注，也激发了人们对治疗性疫苗等创新解决方案的兴趣。随着个人和医疗系统寻求有效应对各种健康挑战的途径，人们对疾病预防重要性的认识不断提高，预计将推动治疗性疫苗的需求成长。随着越来越多的人将接种疫苗作为积极主动的健康管理方式，治疗性疫苗市场预计将迎来显着成长。这反映了医疗保健优先事项的不断变化以及为改善全球人民健康状况所做的共同努力。

限制全球治疗性疫苗市场的因素

全球治疗性疫苗市场面临许多限制因素，这些疫苗在最终惠及全球患者之前，必须经过严格的核准和测试流程。相关程序需要广泛的评估，耗时且复杂，导致延误，阻碍了新疗法快速上市。漫长的审批週期最终限制了市场的成长潜力，因为缓慢的产品核可会扼杀创新，并限制有需要的患者获得突破性治疗方法的机会。

全球治疗性疫苗市场趋势

全球治疗性疫苗市场正呈现出显着的趋势，即整合创新的免疫疗法，尤其是在癌症治疗领域。供应商正致力于开发针对特定肿瘤的特异性治疗性疫苗，以调节其免疫反应。这项策略转变旨在提高现有免疫疗法的疗效，并为患者提供更个人化和有效的治疗方案。随着我们对肿瘤免疫学的理解不断加深，在对能够更有效地利用人体免疫系统对抗癌症的标靶治疗的需求驱动下，市场有望迎来成长。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

GlaxoSmithKline plc（GSK）（United Kingdom）
Sanofi SA（France）
Pfizer Inc.（United States）
Moderna, Inc.（United States）
BioNTech SE（Germany）
Bavarian Nordic A/S（Denmark）
Medigene AG（Germany）
Arbutus Biopharma Corporation（Canada）
Inovio Pharmaceuticals, Inc.（United States）
Dynavax Technologies Corporation（United States）
Agenus Inc.（United States）
Heat Biologics, Inc.（United States）
Northwest Biotherapeutics, Inc.（United States）
ImmunoCellular Therapeutics, Ltd.（United States）
Advaxis, Inc.（United States）
OncoSec Medical Incorporated（United States）
Vical Incorporated（United States）
Celldex Therapeutics, Inc.（United States）
Altimmune, Inc.（United States）

结论与建议

简介目录

Product Code: SQMIG35J2111

Global Therapeutic Vaccines Market size was valued at USD 59.35 Billion in 2024 and is poised to grow from USD 65.58 Billion in 2025 to USD 145.77 Billion by 2033, growing at a CAGR of 10.5% during the forecast period (2026-2033).

The therapeutic vaccines market is experiencing significant growth as these vaccines are administered to enhance immune responses in patients undergoing treatment for chronic diseases, thereby improving recovery prospects. The increasing prevalence of chronic illnesses, coupled with heightened investments in research and development of innovative vaccines, is expected to drive market expansion. Additionally, there is a rising awareness of preventive healthcare and a growing preference for personalized medicine on a global scale, which further fuels demand for therapeutic vaccines. However, challenges such as the complex R&D processes and limited efficacy may hinder long-term market development. To create new opportunities, therapeutic vaccine companies can explore integration with various immunotherapies and precision medicine strategies in the evolving healthcare landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Therapeutic Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Therapeutic Vaccines Market Segments Analysis

Global Therapeutic Vaccines Market is segmented by Products, Technology and region. Based on Products, the market is segmented into Addiction Vaccines, Autoimmune Disease Vaccines, Infectious Disease Vaccines and Neurological Disease Vaccines. Based on Technology, the market is segmented into Autologous vaccines and Allogeneic vaccines. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Therapeutic Vaccines Market

The rising prevalence of infectious and chronic diseases globally has heightened public awareness of preventive healthcare, leading to an increased focus on innovative solutions such as therapeutic vaccines. This growing recognition of the importance of disease prevention is expected to drive demand for therapeutic vaccines, as individuals and healthcare systems alike seek effective measures to combat various health challenges. As more people prioritize vaccination as a proactive approach to health management, the therapeutic vaccines market stands poised for substantial growth, reflecting the evolving landscape of healthcare priorities and the collective push towards improved health outcomes for populations worldwide.

Restraints in the Global Therapeutic Vaccines Market

The Global Therapeutic Vaccines market faces significant constraints due to the stringent approval and testing processes these vaccines must navigate prior to being available for patient use globally. The involved procedures require extensive evaluation and can be both lengthy and intricate, resulting in delays that hinder the prompt introduction of new therapies to the market. This protracted timeline ultimately restricts the growth potential of the market, as the slow pace of product approval can stall innovation and limit the availability of potentially groundbreaking treatments for patients in need.

Market Trends of the Global Therapeutic Vaccines Market

The Global Therapeutic Vaccines market is experiencing a notable trend towards the integration of innovative immunotherapy approaches, particularly for cancer treatment. Vendors are increasingly focusing on the development of specialized therapeutic vaccines tailored to modulate immune responses specific to various tumors. This strategic pivot aims to enhance the efficacy rates of existing immunotherapies, providing more personalized and effective treatment options for patients. As understanding of tumor immunology advances, the market is poised for growth, driven by the need for improved targeted therapies that leverage the body's immune system to combat cancer more effectively.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Therapeutic Vaccines Market Size by Products & CAGR (2026-2033)

Market Overview
Addiction Vaccines
Autoimmune Disease Vaccines
Infectious Disease Vaccines
Neurological Disease Vaccines

Global Therapeutic Vaccines Market Size by Technology & CAGR (2026-2033)

Market Overview
Autologous vaccines
Allogeneic vaccines

Global Therapeutic Vaccines Market Size & CAGR (2026-2033)

North America (Products, Technology)
- US
- Canada
Europe (Products, Technology)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Products, Technology)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Products, Technology)
- Brazil
- Rest of Latin America
Middle East & Africa (Products, Technology)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

GlaxoSmithKline plc (GSK) (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Moderna, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioNTech SE (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bavarian Nordic A/S (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medigene AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arbutus Biopharma Corporation (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Inovio Pharmaceuticals, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dynavax Technologies Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agenus Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Heat Biologics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Northwest Biotherapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ImmunoCellular Therapeutics, Ltd. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Advaxis, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OncoSec Medical Incorporated (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vical Incorporated (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celldex Therapeutics, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Altimmune, Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments